LifeStance Health Group, Inc. (NASDAQ:LFST) Shares Acquired by JPMorgan Chase & Co.

JPMorgan Chase & Co. raised its stake in LifeStance Health Group, Inc. (NASDAQ:LFST) by 13.0% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 94,636 shares of the company’s stock after buying an additional 10,894 shares during the quarter. JPMorgan Chase & Co.’s holdings in LifeStance Health Group were worth $662,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in LFST. Wellington Management Group LLP grew its stake in LifeStance Health Group by 15.2% in the 3rd quarter. Wellington Management Group LLP now owns 4,830,441 shares of the company’s stock valued at $33,813,000 after buying an additional 638,385 shares during the last quarter. Principal Financial Group Inc. increased its stake in shares of LifeStance Health Group by 6.1% in the 3rd quarter. Principal Financial Group Inc. now owns 4,116,766 shares of the company’s stock valued at $28,817,000 after buying an additional 235,316 shares during the period. Geode Capital Management LLC boosted its position in shares of LifeStance Health Group by 26.8% in the 3rd quarter. Geode Capital Management LLC now owns 3,452,178 shares of the company’s stock worth $24,170,000 after purchasing an additional 729,794 shares during the last quarter. State Street Corp lifted its holdings in LifeStance Health Group by 4.7% during the third quarter. State Street Corp now owns 2,750,656 shares of the company’s stock worth $19,255,000 after acquiring an additional 122,844 shares in the last quarter. Finally, Jennison Associates LLC lifted its holdings in LifeStance Health Group by 9.5% during the third quarter. Jennison Associates LLC now owns 2,136,942 shares of the company’s stock worth $14,959,000 after acquiring an additional 184,896 shares in the last quarter. Institutional investors and hedge funds own 85.50% of the company’s stock.

Insiders Place Their Bets

In related news, Director Robert Bessler sold 75,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $7.54, for a total value of $565,500.00. Following the sale, the director now owns 1,424,447 shares in the company, valued at $10,740,330.38. This represents a 5.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. 6.60% of the stock is currently owned by insiders.

LifeStance Health Group Stock Performance

Shares of LifeStance Health Group stock opened at $8.00 on Tuesday. The company has a current ratio of 1.32, a quick ratio of 1.32 and a debt-to-equity ratio of 0.19. The business has a 50-day moving average price of $7.53 and a two-hundred day moving average price of $6.85. LifeStance Health Group, Inc. has a 1-year low of $4.64 and a 1-year high of $9.20. The company has a market cap of $3.06 billion, a P/E ratio of -30.77 and a beta of 1.26.

LifeStance Health Group (NASDAQ:LFST) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($0.02) EPS for the quarter, beating the consensus estimate of ($0.07) by $0.05. LifeStance Health Group had a negative net margin of 7.90% and a negative return on equity of 6.66%. The firm had revenue of $312.70 million during the quarter, compared to analyst estimates of $302.25 million. During the same quarter last year, the business posted ($0.17) EPS. The company’s revenue for the quarter was up 18.9% on a year-over-year basis. As a group, analysts anticipate that LifeStance Health Group, Inc. will post -0.2 EPS for the current year.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on LFST shares. Barclays lifted their target price on LifeStance Health Group from $6.00 to $7.00 and gave the stock an “underweight” rating in a report on Monday, November 11th. The Goldman Sachs Group upgraded LifeStance Health Group from a “neutral” rating to a “buy” rating and set a $10.00 price target on the stock in a report on Monday, December 16th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $8.70.

About LifeStance Health Group

LifeStance Health Group, Inc, through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy.